In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Onyx Pharmaceuticals, Inc.

http://www.onyx-pharm.com

Latest From Onyx Pharmaceuticals, Inc.

Cerevel Goes Public In SPAC Merger To Fund Neuroscience Programs

Deal Snapshot: The $445m Cerevel gains will help as it plans to have at least six programs in the clinic within the next year. CEO Tony Coles will head up a public firm for the first time since Amgen bought Onyx. 

Deals M & A

How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed

US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.

Coronavirus COVID-19 Manufacturing

Opioid Labeling Instructions On Naloxone Are Compromise In Co-Prescribing Debate

US FDA says opioid and opioid use disorder treatment labels should suggest providers discuss naloxone availability with patients and caregivers and consider co-prescribing to patients at high-risk of overdose, but it does not mandate co-prescribing, the most aggressive (and costly) option that had been considered.

Drug Safety Neurology

Stem Cells For COVID-19: Promising Platform With A ‘Dark Side’

Mesenchymal stem cells have encouraging early data in ARDS, but the stem cell industry’s shady reputation complicates perception – and trial enrollment.

Regenerative Medicine Coronavirus COVID-19
See All

Company Information

  • Other Names / Subsidiaries
    • Proteolix, Inc.
UsernamePublicRestriction

Register